Decipher Labs Past Earnings Performance
Past criteria checks 0/6
Decipher Labs's earnings have been declining at an average annual rate of -8.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 23.4% per year.
Key information
-8.8%
Earnings growth rate
-9.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 23.4% |
| Return on equity | -23.8% |
| Net Margin | -14.0% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Decipher Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 351 | -49 | 293 | 0 |
| 30 Sep 23 | 378 | -127 | 347 | 0 |
| 30 Jun 23 | 425 | -95 | 386 | 0 |
| 31 Mar 23 | 456 | -27 | 413 | 0 |
| 31 Dec 22 | 591 | 13 | 461 | 0 |
| 30 Sep 22 | 617 | 163 | 466 | 0 |
| 30 Jun 22 | 645 | 166 | 467 | 0 |
| 31 Mar 22 | 653 | 114 | 475 | 0 |
| 31 Dec 21 | 561 | 102 | 479 | 0 |
| 30 Sep 21 | 562 | 30 | 464 | 0 |
| 30 Jun 21 | 547 | 19 | 460 | 0 |
| 31 Mar 21 | 556 | 14 | 475 | 0 |
| 31 Dec 20 | 591 | 13 | 510 | 0 |
| 30 Sep 20 | 490 | 15 | 428 | 0 |
| 30 Jun 20 | 368 | 12 | 319 | 0 |
| 31 Mar 20 | 240 | 11 | 196 | 0 |
| 31 Dec 19 | 76 | 5 | 48 | 0 |
| 30 Sep 19 | 45 | 4 | 23 | 0 |
| 30 Jun 19 | 46 | 4 | 17 | 0 |
| 31 Mar 19 | 81 | 4 | 11 | 0 |
| 31 Dec 18 | 72 | 4 | 4 | 0 |
| 30 Sep 18 | 69 | 3 | 2 | 0 |
| 30 Jun 18 | 58 | 3 | 3 | 0 |
| 31 Mar 18 | 10 | 2 | 3 | 0 |
| 31 Dec 17 | 7 | 1 | 2 | 0 |
| 30 Sep 17 | 5 | 0 | 2 | 0 |
| 30 Jun 17 | 4 | -2 | 2 | 0 |
| 31 Mar 17 | 4 | -2 | 2 | 0 |
| 31 Dec 16 | 3 | -10 | 3 | 0 |
| 30 Sep 16 | 3 | -9 | 2 | 0 |
| 30 Jun 16 | 2 | -13 | 1 | 0 |
| 31 Mar 16 | 2 | -13 | 1 | 0 |
| 31 Dec 15 | 2 | -28 | 2 | 0 |
| 30 Sep 15 | 1 | -40 | 2 | 0 |
| 30 Jun 15 | 1 | -37 | 0 | 0 |
| 31 Mar 15 | 1 | -37 | 1 | 0 |
| 31 Dec 14 | 2 | -20 | 3 | 0 |
| 30 Sep 14 | 1 | -7 | 3 | 0 |
| 30 Jun 14 | 0 | -8 | 1 | 0 |
| 31 Mar 14 | 0 | -8 | 3 | 0 |
| 31 Dec 13 | 2 | -2 | 1 | 0 |
| 30 Sep 13 | 2 | -2 | 1 | 0 |
| 30 Jun 13 | 2 | -2 | 0 | 0 |
Quality Earnings: 524752 is currently unprofitable.
Growing Profit Margin: 524752 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524752 is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare 524752's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524752 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 524752 has a negative Return on Equity (-23.84%), as it is currently unprofitable.